Program
Tadalafil
Also written as “tadalafil”, “Tadalafil 20 mg” and “Cialis Tab. 5mg”.
Its studies are mostly in Erectile Dysfunction · Prostatic Hyperplasia · Hypertension, Pulmonary · Pulmonary Arterial Hypertension · Carcinoma, Non-Small-Cell Lung, led by 8 companies.
Drug pageTadalafil: every studyMany companies study it; this page follows only the 59 they lead. All 193 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 490 open or running | phase 4since May 31, 2006 | Dec 16, 2002 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 30 open or running | phase 3since Sep 2, 2015 | Sep 15, 2014 | none ahead |
| Pfizerits history only | 20 open or running | phase 2since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| Futura Medical Developmentsits history only | 10 open or running | phase 3since Jul 26, 2021 | Jul 26, 2021 | none ahead |
| Hanmi Pharmaceuticalits history only | 10 open or running | phase 1since Sep 4, 2014 | Sep 4, 2014 | none ahead |
| lidia-larran-agaits history only | 10 open or running | phase 3since May 6, 2020 | May 6, 2020 | none ahead |
| Sanofiits history only | 10 open or running | phase 3since Jan 17, 2025 | Jan 17, 2025 | none ahead |
| Seattle Gummyits history only | 11 open or running | phase 1since Feb 17, 2021 | Feb 17, 2021 | none ahead |
Also a collaborator on its studies: Bristol-Myers Squibb, Gilead Sciences, Nippon Shinyaku and ICOS.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 44 studies since Dec 16, 2002.
- Apr 1, 2013Phase 3 study in Hypertension, PulmonaryEli Lilly · NCT01824290 · 35 enrolled · United States, Austria, Belgium and more
- May 24, 2013Phase 3 study in Muscular Dystrophy, DuchenneEli Lilly · NCT01865084 · 331 enrolled · United States, Argentina, Belgium and more
- Sep 4, 2013Phase 3 study in Prostatic HyperplasiaEli Lilly · NCT01937871 · 909 enrolled · China
- Jul 17, 2014Phase 2 study in Essential HypertensionEli Lilly · NCT02194465 · 304 enrolled · United States, Canada, Puerto Rico
- Aug 20, 2014Phase 4 study in Erectile DysfunctionEli Lilly · NCT02224846 · 635 enrolled · China
- Sep 4, 2014Hanmi Pharmaceutical’s first study: phase 1 study in Erectile DysfunctionNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT02239484 · 30 enrolled · Korea, Republic of
- Sep 15, 2014Chong Kun Dang Pharmaceutical’s first studies: 2 phase 1 studiesNew to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT02247518, NCT02247505
- Nov 20, 2014Phase 1 study in Healthy VolunteersEli Lilly · NCT02300259 · 48 enrolled · United States
- Apr 28, 2015Phase 4 study in Prostatic HyperplasiaEli Lilly · NCT02431754 · 171 enrolled · Japan
- Sep 2, 2015Phase 3 study in Prostatic HyperplasiaChong Kun Dang Pharmaceutical · NCT03246880 · 455 enrolled · Korea, Republic of
- May 6, 2020lidia-larran-aga’s first study: phase 3 study in Sexual Dysfunctions, PsychologicalNew to lidia-larran-agalidia-larran-aga · NCT04433559 · 80 enrolled
- Feb 17, 2021Seattle Gummy’s first study: phase 1 study in Erectile DysfunctionNew to Seattle GummySeattle Gummy · NCT04762082 · 30 planned
- Jul 26, 2021Futura Medical Developments’ first study: phase 3 study in Erectile DysfunctionNew to Futura Medical DevelopmentsFutura Medical Developments · NCT04984993 · 116 enrolled · United States, Bulgaria, Georgia and more
- Jan 17, 2025Sanofi’s first study: phase 3 study in Erectile DysfunctionNew to SanofiSanofi · NCT06805513 · 2,212 enrolled · United States
TargetBeta
“Phosphodiesterase 5A inhibitor”ChEMBL 37, by rule
Other programs on PDE5A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sildenafilrule | Viatris | phase 4 | 74 |
Studies
All 59 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06805513Erectile Dysfunction · United States | 3 | Completed | Sanofi | Mar 2, 2026 | 2,212 |
| NCT04984993Erectile Dysfunction · United States, Bulgaria, Georgia and more | 3 | Completed | Futura Medical Developments | Jul 13, 2022 | 116 |
| NCT04762082Erectile Dysfunction | 1 | Not yet recruiting | Seattle Gummy | Aug 30, 2025 | 30 |
| NCT04433559Sexual Dysfunctions, Psychological | 3 | UNKNOWN | lidia-larran-aga | Aug 2021 | 80 |
| NCT03246880Prostatic Hyperplasia · Korea, Republic of | 3 | Completed | Chong Kun Dang Pharmaceutical | Apr 2016 | 455 |
| NCT02431754Prostatic Hyperplasia · Japan | 4 | Completed | Eli Lilly | Feb 2016 | 171 |
| NCT02300259Healthy Volunteers · United States | 1 | Completed | Eli Lilly | Apr 2015 | 48 |
| NCT02247518Healthy · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Oct 2014 | 16 |
| NCT02247505Healty Male Volunteers · Korea, Republic of | 1 | Completed | Chong Kun Dang Pharmaceutical | Oct 2014 | 29 |
| NCT02239484Erectile Dysfunction · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Sep 2014 | 30 |
| NCT02224846Erectile Dysfunction · China | 4 | Completed | Eli Lilly | May 2016 | 635 |
| NCT02194465Essential Hypertension · United States, Canada, Puerto Rico | 2 | Completed | Eli Lilly | Mar 2015 | 304 |
| NCT01937871Prostatic Hyperplasia · China | 3 | Completed | Eli Lilly | Dec 2015 | 909 |
| NCT01865084Muscular Dystrophy, Duchenne · United States, Argentina, Belgium and more | 3 | Terminated | Eli Lilly | Dec 2015 | 331 |
| NCT01824290Hypertension, Pulmonary · United States, Austria, Belgium and more | 3 | Completed | Eli Lilly | Mar 18, 2019 | 35 |
| NCT01484431Pulmonary Arterial Hypertension · United States, Canada, France and more | 2 | Completed | Eli Lilly | Apr 21, 2017 | 20 |
| NCT01460342Prostatic Hyperplasia · Japan, Korea, Republic of | 3 | Completed | Eli Lilly | Oct 2012 | 610 |
| NCT01352507Erectile Dysfunction · China | 4 | Completed | Eli Lilly | Jun 2012 | 383 |
| NCT01244620Pulmonary Arterial Hypertension · Singapore | 1 | Terminated | Pfizer | Dec 2010 | 16 |
| NCT01183650Prostatic Hyperplasia · Germany | 1 | Completed | Eli Lilly | Apr 2011 | 24 |
| NCT01160289Erectile Dysfunction · United States | 2 | Completed | Eli Lilly | Nov 2011 | 410 |
| NCT01152190Prostatic Hyperplasia · United States, Austria, Italy | 3 | Completed | Eli Lilly | Jul 2012 | 97 |
| NCT01139762Prostatic Hyperplasia · United States, Argentina, Belgium and more | 3 | Completed | Eli Lilly | Feb 2012 | 696 |
| NCT01130532Erectile Dysfunction · United States, Canada | 4 | Completed | Eli Lilly | Jan 2012 | 623 |
| NCT01122264Erectile Dysfunction · France, Germany, Greece and more | 4 | Completed | Eli Lilly | Jun 2011 | 770 |
| NCT01026818Erectile Dysfunction · Belgium, Canada, France and more | 4 | Completed | Eli Lilly | Oct 2012 | 583 |
| NCT00970632Prostatic Hyperplasia · Australia, Austria, Belgium and more | 3 | Completed | Eli Lilly | Jan 2011 | 511 |
| NCT00861757Prostatic Hyperplasia · Japan, Taiwan | 3 | Completed | Eli Lilly | Jun 2010 | 612 |
| NCT00855582Erectile Dysfunction · United States, Canada, France and more | 3 | Completed | Eli Lilly | Jul 2010 | 606 |
| NCT00848081Prostatic Hyperplasia · United States, Puerto Rico | 3 | Completed | Eli Lilly | Dec 2009 | 318 |
| NCT00836693Erectile Dysfunction · Germany, Greece, Italy and more | 3 | Completed | Eli Lilly | Jan 2010 | 217 |
| NCT00833638Erectile Dysfunction · United States | 4 | Completed | Eli Lilly | Jun 2009 | 372 |
| NCT00827242Prostatic Hyperplasia · United States, Argentina, Germany and more | 3 | Completed | Eli Lilly | Nov 2009 | 325 |
| NCT00783094Prostatic Hyperplasia · Japan | 2 | Completed | Eli Lilly | Jun 2009 | 422 |
| NCT00734604Erectile Dysfunction · United States, Australia, Brazil and more | 3 | Completed | Eli Lilly | Sep 2009 | 378 |
| NCT00549302Hypertension, Pulmonary · United States, Belgium, Canada and more | 3 | Completed | Eli Lilly | Feb 2012 | 357 |
| NCT00547625Prostatic Hyperplasia · United States | 2 | Completed | Eli Lilly | 275 | |
| NCT00547599Erectile Dysfunction · Sweden | 4 | Completed | Eli Lilly | 659 | |
| NCT00547573Erectile Dysfunction · China | 3 | Completed | Eli Lilly | 367 | |
| NCT00547508Erectile Dysfunction · United States | 3 | Completed | Eli Lilly | 485 | |
| NCT00547495Erectile Dysfunction · Japan | 3 | Completed | Eli Lilly | 343 | |
| NCT00547417Erectile Dysfunction · United States | 3 | Completed | Eli Lilly | 1,933 | |
| NCT00547352Erectile Dysfunction · Korea, Republic of | 4 | Completed | Eli Lilly | 160 | |
| NCT00547287Erectile Dysfunction · Brazil | 3 | Completed | Eli Lilly | 2,760 | |
| NCT00547183Erectile Dysfunction · Germany | 3 | Completed | Eli Lilly | 298 | |
| NCT00547092Erectile Dysfunction · United Kingdom | 4 | Completed | Eli Lilly | 386 | |
| NCT00540124Prostatic Hyperplasia · Korea, Republic of | 2 | Completed | Eli Lilly | Jun 2008 | 151 |
| NCT00422734Erectile Dysfunction · United States, Austria, France and more | 3 | Completed | Eli Lilly | Jan 2008 | 342 |
| NCT00422578Erectile Dysfunction · Finland | 4 | Completed | Eli Lilly | 200 | |
| NCT00421083Erectile Dysfunction · United States | 3 | Completed | Eli Lilly | 180 | |
| NCT00386009Prostatic Hyperplasia · United States, Greece, Portugal | 2 | Completed | Eli Lilly | May 2008 | 200 |
| NCT00384930Prostatic Hyperplasia · United States | 3 | Completed | Eli Lilly | Oct 2007 | 1,058 |
| NCT00382135Erectile Dysfunction · United States | 4 | Completed | Eli Lilly | 282 | |
| NCT00381732Erectile Dysfunction · United States | 3 | Completed | Eli Lilly | 280 | |
| NCT00333281Erectile Dysfunction · United States | 4 | Completed | Eli Lilly | 198 | |
| NCT00174486Erectile Dysfunction | 2 | Completed | Pfizer | 300 | |
| NCT00157326Hypertension · United States | 2 | Completed | Eli Lilly | 180 | |
| NCT00125918Hypertension, Pulmonary · United States, France, Italy | 3 | Completed | Eli Lilly | Aug 2007 | 406 |
| NCT00050609Gastroparesis · Canada | 2 | Completed | Eli Lilly | 2 |
How it is read
Names in the registry
- “tadalafil”, 45 entries
- “Tadalafil”, 25 entries
- “Tadalafil 20 mg”, 2 entries
- “Cialis Tab. 5mg”, 2 entries
- “Tadalafil 5 mg”, 2 entries
Conditions, from the studies’ own filings
- Erectile Dysfunction, 32 studies
- Prostatic Hyperplasia, 18 studies
- Hypertension, Pulmonary, 4 studies
- Pulmonary Arterial Hypertension, 4 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.